Indeed, inclusion of CD4+ T-cell epitopes from influenza hemagglutinin (S1) or the synthetic CD4+ T-cell epitope PADRE fully activated GUCY2C-specific CD8+ T and B cells, improving vaccine antitumor efficacy > 750%, without autoimmunity [17, 18]. This evidence concerns the gene CD4 and Autoimmunity.